Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
73.26 USD | +1.57% | +1.23% | +2.29% |
Sales 2024 * | 662M 55.16B | Sales 2025 * | 923M 76.93B | Capitalization | 7.72B 644B |
---|---|---|---|---|---|
Net income 2024 * | -59M -4.92B | Net income 2025 * | 108M 9B | EV / Sales 2024 * | 10.5 x |
Net cash position 2024 * | 755M 62.94B | Net cash position 2025 * | 839M 69.99B | EV / Sales 2025 * | 7.46 x |
P/E ratio 2024 * |
-117
x | P/E ratio 2025 * |
64.6
x | Employees | 610 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.56% |
Latest transcript on Intra-Cellular Therapies, Inc.
1 day | +1.57% | ||
1 week | +1.23% | ||
Current month | +5.87% | ||
1 month | +8.81% | ||
3 months | +8.74% | ||
6 months | +52.50% | ||
Current year | +2.29% |
Managers | Title | Age | Since |
---|---|---|---|
Sharon Mates
CEO | Chief Executive Officer | 71 | 29/13/29 |
Director of Finance/CFO | 67 | 29/13/29 | |
Michael Halstead
PSD | President | 51 | 01/14/01 |
Members of the board | Title | Age | Since |
---|---|---|---|
Rory Riggs
BRD | Director/Board Member | 71 | 08/14/08 |
Joel Marcus
BRD | Director/Board Member | 76 | 29/13/29 |
Director/Board Member | 67 | 08/14/08 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
1.14% | 16 M€ | -8.49% | ||
0.45% | 0 M€ | 0.00% | - | |
0.40% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
26/24/26 | 73.26 | +1.57% | 594,803 |
25/24/25 | 72.13 | -1.35% | 658,777 |
24/24/24 | 73.12 | -1.20% | 736,512 |
23/24/23 | 74.01 | -0.71% | 826,601 |
22/24/22 | 74.54 | +3.00% | 1,927,853 |
Delayed Quote Nasdaq, April 27, 2024 at 01:30 am IST
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+2.29% | 7.72B | |
-4.66% | 86.13B | |
+1.32% | 39.82B | |
-19.27% | 30.42B | |
+57.86% | 25.23B | |
-17.69% | 11.6B | |
-43.00% | 11.51B | |
-9.14% | 11.95B | |
+5.24% | 8.71B | |
-8.42% | 8.12B |
- Stock Market
- Equities
- ITCI Stock